Business
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye REDWOOD CITY, Calif.,
About this update from Rezolute, Inc.
[{"type":"text","content":"RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye\nREDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, yesterday hosted a virtual key opinion leader (KOL) event focused on the therapeutic landscape of Diabetic Macular Edema (DME), scientific rationale for an oral plasma kallikrein inhibitor (PKI) to target the disease, and the potential of RZ402, the company’s oral PKI, to change the standard of care as a safe, effective, and less invasive treatment option. “We were honored to have Robert Bhisitkul, MD, PhD, yesterday to share his insights for RZ402 and the current treatment landscape for DME from his perspective as a practicing physician and retina specialist,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “The frequency of intravitreal therapeutic injections for diseases like DME prove to be a heavy burden on not only the patient, but the physicians who can’t maintain pace with the treatment regimens. Dr. Bhisitkul’s view on the unmet medical need for an oral treatment option for DME that can improve patient compliance and begin treatment earlier in the course of the disease supports development of RZ402 as a first-line monotherapy.” “The current clinical treatments of DME, especially treatment regimens utilizing anti-VEGF drugs and second-line steroid treatments, are encumbered with limitations and present an opportunity for RZ402 to truly change the standard of care,” said Dr. Bhisitkul. “I am excited by the potential of RZ402 to be deployed early in disease state and prevent disease progression in patients with DME though its broad spectrum of anti-inflammation and anti-leakage mechanism of actions. An oral alternative to intravitreal injections may reduce or eliminate the need for anti-VEGF injections, expanding the treatment population while simultaneously reducing the treatment burden on the clinic.” In December 2022, Rezolute announced the initiation of a Phase 2 study of RZ402 in patients with DME. The Phase 2 study is a multi-center, randomized, double-masked, placebo-controlled, parallel-arm stu...